Coherus Oncology
Logotype for Coherus Oncology Inc

Coherus Oncology (CHRS) investor relations material

Coherus Oncology Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Coherus Oncology Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Strategic focus and operating model

  • Development focus narrowed to tagmokitug and esophageal cancer after completing studies across six indications; estimated global esophageal cancer population is 400,000–500,000.

  • Headcount reduced from about 140 to about 100; quarterly burn lowered by $6 million–$7 million, with the sales hurdle for core cash burn reduced to $25 million–$30 million per quarter.

  • Pasritamig prostate study with J&J was expected to dose its first patient that week or the following week; rationale is that Treg depletion may remodel the tumor microenvironment for T-cell engagement.

Tagmokitug clinical results

  • First-line esophageal data updated from 6/8 responders (75%) to 8/9 (89%) after the Oct. 14 data cut; ORR was 100% among PD-L1-positive patients.

  • Interim ctDNA declines tracked with partial or complete responses among patients with available samples; one patient may have had complete ctDNA disappearance.

  • Second-line esophageal results included 33% confirmed and 44% unconfirmed ORR versus about 10% for chemotherapy; median PFS was 5.5 months versus 2.5–3.5 months for standard-of-care chemotherapy.

  • First-line discontinuations attributed to treatment-related adverse events from tagmokitug included cases the speaker said were due to chemotherapy; follow-on studies plan to change the chemotherapy regimen.

Development plans and partnering

  • Planned first step is an FDA discussion on second-line esophageal development and a potential accelerated-approval strategy; a randomized study would enroll patients progressing after first-line PD-1 plus chemotherapy.

  • Proposed second-line study would compare the triplet with physician-choice chemotherapy; ORR is the primary endpoint, with PFS and OS as secondary endpoints, and 1:1 or 2:1 randomization under discussion.

  • The regulatory package was being prepared for filing by year-end; the proposed trial is multi-regional, with partnership discussions underway in Asia, including Japan, Korea and China.

  • First-line plan is tagmokitug plus PD-1 and chemotherapy versus PD-1 plus chemotherapy, with potential activity irrespective of PD-L1 status.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Coherus Oncology earnings date

Logotype for Coherus Oncology Inc
Q4 20268 Mar, 2027
Coherus Oncology
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Coherus Oncology earnings date

Logotype for Coherus Oncology Inc
Q4 20268 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company seeks to create rationally designed molecules for important therapeutic targets that have been the targets of drugs or biological products that are either currently approved or in clinical development for inflammatory, metabolic, autoimmune/lupus, nephrology and cardiovascular/vascular diseases. Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, California.